Key points are not available for this paper at this time.
: There is light on the horizon that new treatment options will be available in due time, as there are several promising therapeutic agents currently under investigation, some being at the first levels of drug development, but some already in ongoing clinical trials (phase I-III).
Weigert et al. (Tue,) studied this question.